Herbalife Ltd

The stock remains in a Stage 4 decline with a confirmed lower-high/lower-low structure under declining EMAs; medium-term bias is bearish per stage and downtrend, while short-term timing shows a bullish pullback into the 9/21/50 EMA zone—execution should be deferred into that resistance area for a rejection-based sell.

• ↑Q1 2026 net sales $1.3 B (+7.8% YoY), strongest growth since Q2 2021.
• ↑Bionic acquisition accelerates personalized vitamin/mineral portfolio rollout.
• ↓Full-year 2024 sales seen down 1.5%, signaling revenue stagnation.